Articles by James Calloway
Opendoor's Aggressive 4.99% Mortgage Beta Tests Profitability Path
Opendoor Technologies introduced a beta mortgage product with a 4.99% rate to stimulate transactions, as the iBuyer works to achieve profitability by late 2026 following significant annual losses.
UiPath Shares Dip Ahead of Q4 Report Amid AI Strategy Scrutiny
UiPath shares fell slightly on Monday as the market awaits the company's fourth-quarter results, focusing on whether its new AI tools can drive sustainable growth amid rising competition.
Ford Issues Massive Recall for 1 Million Vehicles, Stock Dips
Ford Motor Company is initiating a recall covering approximately 1.02 million vehicles in the United States due to windshield wiper motor and rear suspension issues. The automaker's shares declined about 1% following the announcement.
Petrobras Stock Rises on Oil Price Rally, Dividend Outlook in Focus
Petrobras shares climbed 4.3% Monday as surging crude prices renewed discussions about additional shareholder returns. The Brazilian oil giant reported a Q4 net profit of 15.6 billion reais, though executives indicated extra dividends are unlikely this year.
Costco Holds Cash, Focuses on Digital Growth After Strong Quarter
Costco posted quarterly sales of $68.24 billion and net income of $2.04 billion, exceeding forecasts. The company holds $17.38 billion in cash but has no immediate plans for a special dividend, focusing instead on warehouse expansion and digital investments.
Red Cat Shares Retreat After Pentagon Drone Shortlist, Q4 Revenue Surge Awaited
Red Cat Holdings shares declined approximately 4% Monday after its drone unit was named a finalist for Pentagon contracts, tempering a recent rally. The company anticipates reporting a massive year-over-year revenue increase for its fourth quarter on March 18.
Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.
Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling
Unusual Machines shares climbed 7% Monday following preliminary results showing 2025 revenue more than doubled to $11.2 million and cash reserves topped $103 million. The drone components maker also reported a widened quarterly operating loss.
W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief
W&T Offshore disclosed a deeper net loss for 2025, with revenue declining to $501.5 million. The company highlighted reduced net debt and potential regulatory relief from proposed offshore financial assurance rules.
Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting
Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.